Myocardial Infarction (MI) Treatment

Myocardial Infarction (MI) Treatment

Global Myocardial Infarction (MI) Treatment Market to Reach US$2.1 Billion by 2030

The global market for Myocardial Infarction (MI) Treatment estimated at US$1.7 Billion in the year 2023, is expected to reach US$2.1 Billion by 2030, growing at a CAGR of 3.0% over the analysis period 2023-2030. Antiplatelet Agents, one of the segments analyzed in the report, is expected to record a 3.9% CAGR and reach US$954.6 Million by the end of the analysis period. Growth in the Glycoprotein IIb / IIIa Inhibitors segment is estimated at 2.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$469.8 Million While China is Forecast to Grow at 6.0% CAGR

The Myocardial Infarction (MI) Treatment market in the U.S. is estimated at US$469.8 Million in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$434.9 Million by the year 2030 trailing a CAGR of 6.0% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.8% and 2.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.5% CAGR.

Global Myocardial Infarction (MI) Treatment Market - Key Trends and Drivers Summarized

Myocardial infarction (MI), commonly known as a heart attack, occurs when blood flow to a part of the heart is blocked for a long enough time that part of the heart muscle is damaged or dies. The most common cause of MI is the buildup of fatty deposits on the walls of coronary arteries, which form plaques. When these plaques rupture, a blood clot can form and obstruct the blood flow. Immediate treatment is crucial to restore blood flow and minimize heart damage. The primary treatment for MI includes medications such as antiplatelets, anticoagulants, thrombolytics, beta-blockers, and ACE inhibitors. These drugs help dissolve clots, reduce the heart`s workload, and prevent further clot formation. In addition to medication, invasive procedures like angioplasty and stent placement, as well as coronary artery bypass grafting (CABG), are often necessary to reopen blocked arteries and restore blood flow.

Advancements in technology have significantly improved the outcomes of MI treatment. The development of drug-eluting stents, which release medication to prevent artery re-blockage, has revolutionized angioplasty procedures. Moreover, the use of advanced imaging techniques such as intravascular ultrasound (IVUS) and optical coherence tomography (OCT) allows for precise assessment of arterial blockages and better planning of interventions. Telemedicine and remote monitoring technologies have also made it possible for healthcare providers to monitor patients` heart health more closely and respond quickly to signs of a potential MI. Furthermore, the implementation of comprehensive cardiac rehabilitation programs, which include exercise training, dietary counseling, and psychological support, has proven to be effective in improving the long-term outcomes and quality of life for MI patients.

The growth in the myocardial infarction treatment market is driven by several factors. Advances in medical technology, such as the development of minimally invasive surgical techniques and more effective drug therapies, are propelling market expansion. The increasing prevalence of cardiovascular diseases due to aging populations and lifestyle factors like poor diet, lack of exercise, and smoking is also driving demand for MI treatments. Additionally, heightened awareness about the importance of early diagnosis and intervention, supported by public health initiatives and education campaigns, is leading to more timely and effective treatments. The rise of personalized medicine, which tailors treatment plans to individual patient profiles based on genetic, environmental, and lifestyle factors, is another significant driver. Innovations in wearable health technologies and mobile health applications that facilitate continuous monitoring and early detection of heart issues are further contributing to market growth. Moreover, robust healthcare infrastructure in developed regions and improving access to healthcare services in emerging markets are expanding the reach of MI treatments. As healthcare providers continue to adopt new technologies and methods, the market for myocardial infarction treatments is expected to experience sustained growth.

Select Competitors (Total 86 Featured) -
  • A. Menarini Industrie Farmaceutiche Riunite Srl
  • Amgen, Inc.
  • Arrowhead Pharmaceuticals, Inc.
  • Bayer AG
  • Biocardia, Inc.
  • Boehringer Ingelheim International GmbH
  • CellProthera
  • CSL Ltd.
  • Daiichi Sankyo Co., Ltd.
  • Faraday Pharmaceuticals
  • Kancera AB
  • Nordic Bioscience A/S
  • Tenaya Therapeutics
  • Viatris Inc.
Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.


I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
Global Economic Update
Myocardial Infarction (MI) Treatment - Global Key Competitors Percentage Market Share in 2024 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Increasing Prevalence of Cardiovascular Diseases Expands Addressable Market Opportunity
Advances in Minimally Invasive Surgical Techniques Propel Growth
Development of Effective Drug Therapies Strengthens Business Case for Treatment Adoption
Aging Population and Lifestyle Factors Drive Demand for MI Treatments
Heightened Awareness of Early Diagnosis and Intervention Spurs Market Expansion
Rise of Personalized Medicine Strengthens Business Case for Customized Treatments
Mobile Health Applications Facilitate Continuous Monitoring and Drive Adoption
Robust Healthcare Infrastructure in Developed Regions Sustains Growth
Improving Access to Healthcare Services in Emerging Markets Expands Reach
Technological Advancements in Imaging Techniques Enhance Treatment Precision
Increasing Utilization of Telemedicine Throws the Spotlight on Remote Monitoring
Enhanced Patient Outcomes with Drug-Eluting Stents Drive Market Adoption
Implementation of Artificial Intelligence in Diagnosis and Treatment Planning Spurs Growth
Focus on Reducing Healthcare Costs Through Effective MI Management Expands Market Opportunity
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Myocardial Infarction (MI) Treatment Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
TABLE 2: World Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 3: World Historic Review for Myocardial Infarction (MI) Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 4: World 16-Year Perspective for Myocardial Infarction (MI) Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
TABLE 5: World Recent Past, Current & Future Analysis for Antiplatelet Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 6: World Historic Review for Antiplatelet Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 7: World 16-Year Perspective for Antiplatelet Agents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 8: World Recent Past, Current & Future Analysis for Glycoprotein IIb / IIIa Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 9: World Historic Review for Glycoprotein IIb / IIIa Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 10: World 16-Year Perspective for Glycoprotein IIb / IIIa Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 11: World Recent Past, Current & Future Analysis for Antithrombotic Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 12: World Historic Review for Antithrombotic Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 13: World 16-Year Perspective for Antithrombotic Agents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 14: World Recent Past, Current & Future Analysis for Beta-Adrenergic Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 15: World Historic Review for Beta-Adrenergic Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 16: World 16-Year Perspective for Beta-Adrenergic Blockers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 17: World Recent Past, Current & Future Analysis for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 18: World Historic Review for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 19: World 16-Year Perspective for Other Drug Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 20: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 21: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 22: World 16-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 23: World Recent Past, Current & Future Analysis for Drug Stores by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 24: World Historic Review for Drug Stores by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 25: World 16-Year Perspective for Drug Stores by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 26: World Recent Past, Current & Future Analysis for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 27: World Historic Review for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 28: World 16-Year Perspective for Online Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
III. MARKET ANALYSIS
UNITED STATES
Myocardial Infarction (MI) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
TABLE 29: USA Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 30: USA Historic Review for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 31: USA 16-Year Perspective for Myocardial Infarction (MI) Treatment by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types for the Years 2014, 2024 & 2030
TABLE 32: USA Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 33: USA Historic Review for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 34: USA 16-Year Perspective for Myocardial Infarction (MI) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2024 & 2030
CANADA
TABLE 35: Canada Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 36: Canada Historic Review for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 37: Canada 16-Year Perspective for Myocardial Infarction (MI) Treatment by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types for the Years 2014, 2024 & 2030
TABLE 38: Canada Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 39: Canada Historic Review for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 40: Canada 16-Year Perspective for Myocardial Infarction (MI) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2024 & 2030
JAPAN
Myocardial Infarction (MI) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
TABLE 41: Japan Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 42: Japan Historic Review for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 43: Japan 16-Year Perspective for Myocardial Infarction (MI) Treatment by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types for the Years 2014, 2024 & 2030
TABLE 44: Japan Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 45: Japan Historic Review for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 46: Japan 16-Year Perspective for Myocardial Infarction (MI) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2024 & 2030
CHINA
Myocardial Infarction (MI) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
TABLE 47: China Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 48: China Historic Review for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 49: China 16-Year Perspective for Myocardial Infarction (MI) Treatment by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types for the Years 2014, 2024 & 2030
TABLE 50: China Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 51: China Historic Review for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 52: China 16-Year Perspective for Myocardial Infarction (MI) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2024 & 2030
EUROPE
Myocardial Infarction (MI) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
TABLE 53: Europe Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 54: Europe Historic Review for Myocardial Infarction (MI) Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 55: Europe 16-Year Perspective for Myocardial Infarction (MI) Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
TABLE 56: Europe Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 57: Europe Historic Review for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 58: Europe 16-Year Perspective for Myocardial Infarction (MI) Treatment by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types for the Years 2014, 2024 & 2030
TABLE 59: Europe Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 60: Europe Historic Review for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 61: Europe 16-Year Perspective for Myocardial Infarction (MI) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2024 & 2030
FRANCE
Myocardial Infarction (MI) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
TABLE 62: France Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 63: France Historic Review for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 64: France 16-Year Perspective for Myocardial Infarction (MI) Treatment by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types for the Years 2014, 2024 & 2030
TABLE 65: France Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 66: France Historic Review for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 67: France 16-Year Perspective for Myocardial Infarction (MI) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2024 & 2030
GERMANY
Myocardial Infarction (MI) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
TABLE 68: Germany Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 69: Germany Historic Review for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 70: Germany 16-Year Perspective for Myocardial Infarction (MI) Treatment by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types for the Years 2014, 2024 & 2030
TABLE 71: Germany Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 72: Germany Historic Review for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 73: Germany 16-Year Perspective for Myocardial Infarction (MI) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2024 & 2030
ITALY
TABLE 74: Italy Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 75: Italy Historic Review for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 76: Italy 16-Year Perspective for Myocardial Infarction (MI) Treatment by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types for the Years 2014, 2024 & 2030
TABLE 77: Italy Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 78: Italy Historic Review for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 79: Italy 16-Year Perspective for Myocardial Infarction (MI) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2024 & 2030
UNITED KINGDOM
Myocardial Infarction (MI) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
TABLE 80: UK Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 81: UK Historic Review for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 82: UK 16-Year Perspective for Myocardial Infarction (MI) Treatment by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types for the Years 2014, 2024 & 2030
TABLE 83: UK Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 84: UK Historic Review for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 85: UK 16-Year Perspective for Myocardial Infarction (MI) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2024 & 2030
SPAIN
TABLE 86: Spain Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 87: Spain Historic Review for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 88: Spain 16-Year Perspective for Myocardial Infarction (MI) Treatment by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types for the Years 2014, 2024 & 2030
TABLE 89: Spain Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 90: Spain Historic Review for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 91: Spain 16-Year Perspective for Myocardial Infarction (MI) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2024 & 2030
RUSSIA
TABLE 92: Russia Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 93: Russia Historic Review for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 94: Russia 16-Year Perspective for Myocardial Infarction (MI) Treatment by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types for the Years 2014, 2024 & 2030
TABLE 95: Russia Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 96: Russia Historic Review for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 97: Russia 16-Year Perspective for Myocardial Infarction (MI) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2024 & 2030
REST OF EUROPE
TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 99: Rest of Europe Historic Review for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 100: Rest of Europe 16-Year Perspective for Myocardial Infarction (MI) Treatment by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types for the Years 2014, 2024 & 2030
TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 102: Rest of Europe Historic Review for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 103: Rest of Europe 16-Year Perspective for Myocardial Infarction (MI) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2024 & 2030
ASIA-PACIFIC
Myocardial Infarction (MI) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 105: Asia-Pacific Historic Review for Myocardial Infarction (MI) Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 106: Asia-Pacific 16-Year Perspective for Myocardial Infarction (MI) Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 108: Asia-Pacific Historic Review for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 109: Asia-Pacific 16-Year Perspective for Myocardial Infarction (MI) Treatment by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types for the Years 2014, 2024 & 2030
TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 111: Asia-Pacific Historic Review for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 112: Asia-Pacific 16-Year Perspective for Myocardial Infarction (MI) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2024 & 2030
AUSTRALIA
Myocardial Infarction (MI) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
TABLE 113: Australia Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 114: Australia Historic Review for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 115: Australia 16-Year Perspective for Myocardial Infarction (MI) Treatment by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types for the Years 2014, 2024 & 2030
TABLE 116: Australia Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 117: Australia Historic Review for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 118: Australia 16-Year Perspective for Myocardial Infarction (MI) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2024 & 2030
INDIA
Myocardial Infarction (MI) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
TABLE 119: India Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 120: India Historic Review for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 121: India 16-Year Perspective for Myocardial Infarction (MI) Treatment by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types for the Years 2014, 2024 & 2030
TABLE 122: India Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 123: India Historic Review for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 124: India 16-Year Perspective for Myocardial Infarction (MI) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2024 & 2030
SOUTH KOREA
TABLE 125: South Korea Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 126: South Korea Historic Review for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 127: South Korea 16-Year Perspective for Myocardial Infarction (MI) Treatment by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types for the Years 2014, 2024 & 2030
TABLE 128: South Korea Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 129: South Korea Historic Review for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 130: South Korea 16-Year Perspective for Myocardial Infarction (MI) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2024 & 2030
REST OF ASIA-PACIFIC
TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 132: Rest of Asia-Pacific Historic Review for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 133: Rest of Asia-Pacific 16-Year Perspective for Myocardial Infarction (MI) Treatment by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types for the Years 2014, 2024 & 2030
TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 135: Rest of Asia-Pacific Historic Review for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 136: Rest of Asia-Pacific 16-Year Perspective for Myocardial Infarction (MI) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2024 & 2030
LATIN AMERICA
Myocardial Infarction (MI) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
TABLE 137: Latin America Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 138: Latin America Historic Review for Myocardial Infarction (MI) Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 139: Latin America 16-Year Perspective for Myocardial Infarction (MI) Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
TABLE 140: Latin America Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 141: Latin America Historic Review for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 142: Latin America 16-Year Perspective for Myocardial Infarction (MI) Treatment by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types for the Years 2014, 2024 & 2030
TABLE 143: Latin America Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 144: Latin America Historic Review for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 145: Latin America 16-Year Perspective for Myocardial Infarction (MI) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2024 & 2030
ARGENTINA
TABLE 146: Argentina Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 147: Argentina Historic Review for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 148: Argentina 16-Year Perspective for Myocardial Infarction (MI) Treatment by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types for the Years 2014, 2024 & 2030
TABLE 149: Argentina Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 150: Argentina Historic Review for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 151: Argentina 16-Year Perspective for Myocardial Infarction (MI) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2024 & 2030
BRAZIL
TABLE 152: Brazil Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 153: Brazil Historic Review for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 154: Brazil 16-Year Perspective for Myocardial Infarction (MI) Treatment by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types for the Years 2014, 2024 & 2030
TABLE 155: Brazil Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 156: Brazil Historic Review for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 157: Brazil 16-Year Perspective for Myocardial Infarction (MI) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2024 & 2030
MEXICO
TABLE 158: Mexico Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 159: Mexico Historic Review for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 160: Mexico 16-Year Perspective for Myocardial Infarction (MI) Treatment by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types for the Years 2014, 2024 & 2030
TABLE 161: Mexico Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 162: Mexico Historic Review for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 163: Mexico 16-Year Perspective for Myocardial Infarction (MI) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2024 & 2030
REST OF LATIN AMERICA
TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 165: Rest of Latin America Historic Review for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 166: Rest of Latin America 16-Year Perspective for Myocardial Infarction (MI) Treatment by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types for the Years 2014, 2024 & 2030
TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 168: Rest of Latin America Historic Review for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 169: Rest of Latin America 16-Year Perspective for Myocardial Infarction (MI) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2024 & 2030
MIDDLE EAST
Myocardial Infarction (MI) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
TABLE 170: Middle East Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 171: Middle East Historic Review for Myocardial Infarction (MI) Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 172: Middle East 16-Year Perspective for Myocardial Infarction (MI) Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
TABLE 173: Middle East Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 174: Middle East Historic Review for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 175: Middle East 16-Year Perspective for Myocardial Infarction (MI) Treatment by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types for the Years 2014, 2024 & 2030
TABLE 176: Middle East Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 177: Middle East Historic Review for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 178: Middle East 16-Year Perspective for Myocardial Infarction (MI) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2024 & 2030
IRAN
TABLE 179: Iran Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 180: Iran Historic Review for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 181: Iran 16-Year Perspective for Myocardial Infarction (MI) Treatment by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types for the Years 2014, 2024 & 2030
TABLE 182: Iran Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 183: Iran Historic Review for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 184: Iran 16-Year Perspective for Myocardial Infarction (MI) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2024 & 2030
ISRAEL
TABLE 185: Israel Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 186: Israel Historic Review for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 187: Israel 16-Year Perspective for Myocardial Infarction (MI) Treatment by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types for the Years 2014, 2024 & 2030
TABLE 188: Israel Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 189: Israel Historic Review for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 190: Israel 16-Year Perspective for Myocardial Infarction (MI) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2024 & 2030
SAUDI ARABIA
TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 192: Saudi Arabia Historic Review for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 193: Saudi Arabia 16-Year Perspective for Myocardial Infarction (MI) Treatment by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types for the Years 2014, 2024 & 2030
TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 195: Saudi Arabia Historic Review for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 196: Saudi Arabia 16-Year Perspective for Myocardial Infarction (MI) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2024 & 2030
UNITED ARAB EMIRATES
TABLE 197: UAE Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 198: UAE Historic Review for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 199: UAE 16-Year Perspective for Myocardial Infarction (MI) Treatment by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types for the Years 2014, 2024 & 2030
TABLE 200: UAE Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 201: UAE Historic Review for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 202: UAE 16-Year Perspective for Myocardial Infarction (MI) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2024 & 2030
REST OF MIDDLE EAST
TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 204: Rest of Middle East Historic Review for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 205: Rest of Middle East 16-Year Perspective for Myocardial Infarction (MI) Treatment by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types for the Years 2014, 2024 & 2030
TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 207: Rest of Middle East Historic Review for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 208: Rest of Middle East 16-Year Perspective for Myocardial Infarction (MI) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2024 & 2030
AFRICA
Myocardial Infarction (MI) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
TABLE 209: Africa Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 210: Africa Historic Review for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 211: Africa 16-Year Perspective for Myocardial Infarction (MI) Treatment by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types for the Years 2014, 2024 & 2030
TABLE 212: Africa Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 213: Africa Historic Review for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
TABLE 214: Africa 16-Year Perspective for Myocardial Infarction (MI) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2024 & 2030
IV. COMPETITION

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings